Marketing & Strategy
Customer-Centric Engagement During COVID-19
Navigating the multichannel maze in COVID 19 times to engage healthcare professionals (HCPs) and patients has been challenging for most local marketing, medical and commercial teams.
In the last few weeks, Health Industry Hub gained insights from several clinicians (GPs, specialists and surgeons) on how the COVID-19 pandemic has impacted their day-to-day world in clinics and with their patients. See infographic below.
In overwhelming times, most HCPs are not looking to engage with the field force in one-on-one virtual meetings or phone calls unless there is a compelling reason to do so, for example, clinical trials, virtual advisory boards, new registration / reimbursement of medicines or medical devices.
Instead, HCPs are interested in receiving valuable, cross-functional medical content that is easy to access and is of benefit to them and/or their patients.
Click on the image below to learn more.
Customer engagement during COVID-19. Fill the gap of reduced field force activities. Health Industry Hub combines expertise in delivering digital health content and measuring engagement with 20+ years industry experience. Created by industry for industry. Contact us.
News & Trends - Pharmaceuticals
Heart Week: Uniting patient and cardiologist voices in shaping a new future for patient outcomes
Coinciding with the start of the Heart Week (9 – 12 May), Professor Gemma Figtree, Interventional Cardiologist and Immediate Past […]
MoreNews & Trends - MedTech & Diagnostics
‘It’s a marathon not a sprint’: Industry leaders chart next steps in medtech’s sustainability journey
Ahead of World Environment Day in June, Jane Crowe, Managing Director of Cardinal Health Australia and New Zealand and Pravin […]
MoreNews & Trends - Pharmaceuticals
Vaccination accounts for almost half of mortality decline in infants
Pharma News: Researchers have mapped the impact of vaccines to mark the 50-year anniversary of the Expanded Programme on Immunisation […]
MoreNews & Trends - Pharmaceuticals
AbbVie, Pfizer and Bayer therapies to be considered at upcoming PBAC intracycle meeting
Pharma News: Therapies from AbbVie, Pfizer and Bayer are due to be considered at the Pharmaceutical Benefits Advisory Committee (PBAC) […]
More